Nanoscope Therapeutics Inc.
Samuel B Barone is currently serving as the Chief Medical Officer at Nanoscope Therapeutics Inc., a clinical-stage biopharmaceutical company focusing on severe vision loss in advanced retinal disease. Samuel B is also a Principal at SBMD Innovations, LLC, providing strategic consulting services in various medical fields. With a background in ophthalmology and gene therapy, Samuel B has held positions such as Chief Medical Officer at Gemini Therapeutics, Inc. and Veloce BioPharma LLC. Prior to their industry roles, Samuel B worked as a physician at Retina Associates and served as a Senior Medical Officer at the FDA. Samuel holds an MD from Pennsylvania State University College of Medicine and a BS in Biology from Boston College.
This person is not in any offices
Nanoscope Therapeutics Inc.
1 followers
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa